title: Mucin expression profile is related to biological and clinical characteristics of intraductal papillary-mucinous tumors of the pancreas.
abstract: OBJECTIVE
  Biologic and clinical characteristics of intraductal papillary-mucinous tumors of the pancreas (IPMTs) were studied in reference to immunohistochemical mucin (MUC1, MUC2, and MUC5AC) expression.
  
  
  METHODS
  Histologic grade, immunohistochemical ki-67 and p53 expression, and findings in imaging tests of 21 IPMTs (9 carcinomas, 6 borderline tumors, and 6 adenomas) were examined according to the mucin expression profile.
  
  
  RESULTS
  IPMTs were divided into groups: M1 group (MUC1+, n = 4), M2 group (MUC2 + MUC1-, n = 12), and M5 group (MUC5AC + MUC1-MUC2-, n = 5). The M2 group was subdivided into M2s (strongly positive) and M2w (weakly positive) groups. The rates of carcinoma in the M1, M2s, M2w, and M5 groups were 100%, 40%, 0%, and 0%, respectively. The Ki-67 labeling indexes were significantly higher in the M1 and M2s groups. p53 staining was positive in 50% and 40% of the IPMTs in the M1 and M2s groups, respectively, but in none of the IPMT in the M2w and M5 groups. Morphologic changes in imaging tests during the observation periods were most remarkable in the M1 group.
  
  
  CONCLUSIONS
  Our results suggest that MUC1 is related to malignant character but MUC5AC alone is related to benign character in IPMTs and that malignant potential of IPMTs expressing MUC2 depends on the degree of MUC2 expression.
authors.affiliation: First Department of Internal Medicine, Sapporo Medical University, School of Medicine, Sapporo, Japan. hideto@nsp.hosp.go.jp
authors.forename: Hideto
authors.initials: H
authors.lastname: Ito
authors.forename: Takao
authors.initials: T
authors.lastname: Endo
authors.forename: Toshikuni
authors.initials: T
authors.lastname: Oka
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matumoto
authors.forename: Tamaki
authors.initials: T
authors.lastname: Abe
authors.forename: Minoru
authors.initials: M
authors.lastname: Toyota
authors.forename: Kohzoh
authors.initials: K
authors.lastname: Imai
authors.forename: Masaaki
authors.initials: M
authors.lastname: Satoh
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Maguchi
authors.forename: Toshiya
authors.initials: T
authors.lastname: Shinohara
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D002291:Carcinoma, Papillary / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D055271:Mucin 5AC; D018396:Mucin-1 / Q000378:metabolism; D055262:Mucin-2; D009077:Mucins / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; C524625:MUC2 protein, human; C524678:MUC5AC protein, human; D055271:Mucin 5AC; D018396:Mucin-1; D055262:Mucin-2; D009077:Mucins; D016159:Tumor Suppressor Protein p53